Exelixis
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2022-2024
All insider trades at Exelixis
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/21/2024 | Sell | Garber, Alan M. | Director | $24.0 | $461,112 |
| 2/23/2024 | Sell | Haley, Patrick J. | EVP, Commercial | $21.5 | $1,008,579 |
| 2/21/2024 | Buy | Johnson, David Edward | Director | $20.7 | $3,932,734 |
| 12/14/2023 | Sell | Haley, Patrick J. | EVP, Commercial | $23.4 | $1,167,500 |
| 12/13/2023 | Sell | Hessekiel, Jeffrey | EVP, General Counsel & Sec | $23.0 | $575,250 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)